EGF and cancer: Here, we investigate the spatiotemporal change in cell states within two cell lines—trastuzumab-sensitive (BT474) and -resistant (BT474R) HER2+ cancer cells in the presence of two endogenous ligands, epidermal growth factor (EGF) and neuregulin1/heregulin (HRG).